Cancer: Limitations of therapies exposed

Vista senzilla d'ítem
dc.contributor.authorCasanovas i Casanovas, Oriol
dc.date.accessioned2020-11-02T09:44:09Z
dc.date.available2020-11-02T09:44:09Z
dc.date.issued2012-04-01
dc.date.updated2020-10-29T15:04:25Z
dc.description.abstractAnti-angiogenic drugs, used for cancer treatment, target blood-vessel formation in tumours. Two studies commented here show that such drugs can reduce the efficiency of other anticancer agents and increase the aggressiveness of tumours.
dc.format.extent6 p.
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/2445/171689
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1038/484044a
dc.relation.ispartofNature, 2012, vol. 484, issue. 7392, p. 44-46
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/281830/EU//STROMALIGN
dc.relation.urihttps://doi.org/10.1038/484044a
dc.rights(c) Springer Science and Business Media LLC, 2012
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationAngiogènesi
dc.subject.classificationMedicaments antineoplàstics
dc.subject.classificationTumors
dc.subject.otherNeovascularization
dc.subject.otherAntineoplastic agents
dc.titleCancer: Limitations of therapies exposed
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
Casanovas News&Views_v6_POST-PRINT.pdf
Mida:
518.27 KB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))